Deutsche Bank Starts Gen-Probe (GPRO) at Buy; Consummate Molecular Diagnostics 'Pro'

Deutsche Bank initiates coverage on Gen-Probe (NASDAQ: GPRO) with a Buy. PT $70.50.

Deutsche analyst says, "GPRO is a leading player in the $4.5+ Bn MDx market, with a premier women's health and blood screening franchise. The company has a successful track record in launching automated testing instruments, having placed over 550 Tigris' in the five years post launch. FY12 is a significant transition year given the imminent launch of Panther (targeting mid vol labs), and a multitude of assays (HPV, Trich. and PCA3). Given our expectations for new product momentum to drive low double digit rev growth in the MT, we rate GPRO shares a Buy."

For an analyst ratings summary and ratings history on Gen-Probe click here. For more ratings news on Gen-Probe click here.

Shares of Gen-Probe closed at $56.50 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• GoPro (GPRO) PT Lowered to $0.50 at Morgan Stanley
• BMO Capital Starts Energy Fuels (UUUU) at Outperform
• Leerink Starts Ligand Pharma (LGND) at Outperform